TY - JOUR
T1 - Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332
T2 - A Report From the Childrens Oncology Group
AU - Million, Lynn
AU - Hayes-Jordan, Andrea
AU - Chi, Yueh Yun
AU - Donaldson, Sarah S.
AU - Wolden, Suzanne
AU - Morris, Carol
AU - Terezakis, Stephanie
AU - Laurie, Fran
AU - Morano, Karen
AU - Fitzgerald, T. J.
AU - Yock, Torunn I.
AU - Rodeberg, David A.
AU - Anderson, James R.
AU - Speights, Rose Anne
AU - Black, Jennifer O.
AU - Coffin, Cheryl
AU - McCarville, Mary Beth
AU - Kao, Simon C.
AU - Hawkins, Douglas S.
AU - Spunt, Sheri L.
AU - Randall, R. Lor
N1 - Funding Information:
This research was supported in part by grants from the National Institutes of Health to the Children’s Oncology Group ( U10CA180886 , U10CA180899 , U10CA098543 , U10CA098413 ), the Quality Assurance Review Center ( U10CA29511 ), the Imaging and Radiation Oncology Core ( U10CA180803 ), and St. Jude Children's Research Hospital ( P30CA21765 and CA23099 ), and by funding from the St. Baldrick’s Foundation, the Seattle Children’s Foundation (from Kat’s Crew Guild through the Sarcoma Research Fund), and the American Lebanese Syrian Associated Charities.
Funding Information:
Disclosures: S.T. received grants from ASELL and Elekta Industries outside the submitted work. F.L. received grants from the National Cancer Institute during the conduct of the study. T.I.Y. received nonfinancial support from MIM Corporation outside the submitted work. J.R.A. received grants from CTEP/ National Cancer Institute, during the conduct of the study; and other from Merck and Co, outside the submitted work. D.S.H. received clinical trial fees paid to Seattle Children’s to offset costs of study conduct; was reimbursed for or provided travel, housing, and food to attend medial advisory board meetings for Loxo Oncology, Bayer, Bristol Myers Squibb, Lilly, and Celgene; and had clinical trial fees paid to Seattle Children’s to offset costs of study conduct from Merck Sharpe Dohme, Eisai, Novartis, Glaxo Smith Kline, Sanofi, Amgen, Jazz Pharmaceuticals, Seattle Genetics, and Incyte. S.L.S. received grants from the National Cancer Institute/Children's Oncology Group, during the conduct of the study; received grants from F. Hoffman-LaRoche Ltd, Novartis, Alex's Lemonade Stand Foundation, Cookies for Kids' Cancer, Bayer Healthcare Phramaceuticals, Inc, Sanofi US Services, Inc, Loxo Oncology, Incyte Corporation, Bristol Myers Squibb, St. Baldrick's Foundation, Pfizer, Inc, and the University of California, Santa Cruz, outside the submitted work.
Publisher Copyright:
© 2021 Elsevier Inc.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Purpose: The ARST0332 trial for pediatric and young adults with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) used risk-based treatment including primary resection with lower-than-standard radiation doses to optimize local control (LC) while minimizing long-term toxicity in those requiring radiation therapy (RT). RT for high-grade NRSTS was based on extent of resection (R0: negative margins, R1: microscopic margins, R2/U: gross disease/unresectable); those with >5 cm tumors received chemotherapy (CT; ifosfamide/doxorubicin). This analysis evaluates LC for patients assigned to RT and prognostic factors associated with local recurrence (LR). Methods and Materials: Patients aged <30 years with high-grade NRSTS received RT (55.8 Gy) for R1 ≤5 cm tumor (arm B); RT (55.8 Gy)/CT for R0/R1 >5 cm tumor (arm C); or neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0 <5 mm margins/R1 or 19.8 Gy for R2/unresected tumors (arm D). Results: One hundred ninety-three eligible patients had 24 LRs (arm B 1/15 [6.7%], arm C 7/65 [10.8%], arm D 16/113 [14.2%]) at median time to LR of 1.1 years (range, 0.11-5.27). Of 95 eligible for delayed surgery after neoadjuvant therapy, 89 (93.7%) achieved R0/R1 margins. Overall LC after RT were as follows: R0, 106 of 109 (97%); R1, 51 of 60 (85%); and R2/unresectable, 2 of 6 (33%). LR predictors include extent of delayed resection (P <.001), imaging response before delayed surgery (P < .001), histologic subtype (P <.001), and no RT (P = .046). The 5-year event-free survival was significantly lower (P = .0003) for patients unable to undergo R0/R1 resection. Conclusions: Risk-based treatment for young patients with high-grade NRSTS treated on ARST0332 produced very high LC, particularly after R0 resection (97%), despite lower-than-standard RT doses. Neoadjuvant CT/RT enabled delayed R0/R1 resection in most patients and is preferred over adjuvant therapy due to the lower RT dose delivered.
AB - Purpose: The ARST0332 trial for pediatric and young adults with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) used risk-based treatment including primary resection with lower-than-standard radiation doses to optimize local control (LC) while minimizing long-term toxicity in those requiring radiation therapy (RT). RT for high-grade NRSTS was based on extent of resection (R0: negative margins, R1: microscopic margins, R2/U: gross disease/unresectable); those with >5 cm tumors received chemotherapy (CT; ifosfamide/doxorubicin). This analysis evaluates LC for patients assigned to RT and prognostic factors associated with local recurrence (LR). Methods and Materials: Patients aged <30 years with high-grade NRSTS received RT (55.8 Gy) for R1 ≤5 cm tumor (arm B); RT (55.8 Gy)/CT for R0/R1 >5 cm tumor (arm C); or neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0 <5 mm margins/R1 or 19.8 Gy for R2/unresected tumors (arm D). Results: One hundred ninety-three eligible patients had 24 LRs (arm B 1/15 [6.7%], arm C 7/65 [10.8%], arm D 16/113 [14.2%]) at median time to LR of 1.1 years (range, 0.11-5.27). Of 95 eligible for delayed surgery after neoadjuvant therapy, 89 (93.7%) achieved R0/R1 margins. Overall LC after RT were as follows: R0, 106 of 109 (97%); R1, 51 of 60 (85%); and R2/unresectable, 2 of 6 (33%). LR predictors include extent of delayed resection (P <.001), imaging response before delayed surgery (P < .001), histologic subtype (P <.001), and no RT (P = .046). The 5-year event-free survival was significantly lower (P = .0003) for patients unable to undergo R0/R1 resection. Conclusions: Risk-based treatment for young patients with high-grade NRSTS treated on ARST0332 produced very high LC, particularly after R0 resection (97%), despite lower-than-standard RT doses. Neoadjuvant CT/RT enabled delayed R0/R1 resection in most patients and is preferred over adjuvant therapy due to the lower RT dose delivered.
UR - http://www.scopus.com/inward/record.url?scp=85102084517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102084517&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2021.01.051
DO - 10.1016/j.ijrobp.2021.01.051
M3 - Article
C2 - 33548339
AN - SCOPUS:85102084517
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
ER -